
News|Articles|December 1, 2012
Escitalopram reduces the risk of depression in patients with HCV treated with interferon alpha
Pre-emptive therapy with the selective serotonin reuptake inhibitor escitalopram in patients initiating interferon therapy for hepatitis C virus (HCV) without psychiatric risk factors reduced the risk of depression, according to a recent study published in the Annals of Internal Medicine.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
What NCCN’s next CMO sees ahead for cancer guidelines, access and innovation
2
Jascayd gets second FDA approval, this time for progressive pulmonary fibrosis
3
5 developments in the treatment of prurgio nodularis in 2025
4
Top 5 stories from Formulary Watch in 2025
5





















































